T细胞免疫球蛋白黏蛋白分子-3在肿瘤免疫中的作用和机制

发布时间：2018-04-27 13:30

本文选题：肿瘤免疫 + 免疫检查点　；参考：《中国肿瘤生物治疗杂志》2017年12期

【摘要】：应用单克隆抗体阻断PD-1、CTLA-4等免疫检查点已在肿瘤免疫治疗中取得了一定成效,但尚有部分患者对免疫检查点阻断剂疗效不佳,其机制可能为存在其他抑制性旁路。T细胞免疫球蛋白黏蛋白分子-3(T cell immunolobulin and mucin-containing protein-3,TIM-3)是一种可表达于多种免疫细胞,并具有重要调控作用的免疫检查点分子。已有研究报道多种肿瘤外周血和肿瘤浸润性T细胞中存在TIM-3高表达,并与预后不良相关。抗肿瘤免疫中,高表达TIM-3的T细胞、DC及单核巨噬细胞,可抑制肿瘤免疫应答。临床前研究显示,抗TIM-3单抗联合抗PD-1单抗可发挥协同抗肿瘤效应。TIM-3单克隆抗体已进入临床试验阶段。然而,TIM-3在调控免疫细胞中的部分功能尚待阐明,进一步理解TIM-3的免疫调节机制有助于推动基于阻断TIM-3抗肿瘤免疫治疗的临床应用。
[Abstract]:The use of monoclonal antibody to block PD-1 CTLA-4 and other immunological checkpoints has achieved some results in tumor immunotherapy, but there are still some patients who have a poor therapeutic effect on immune checkpoint blockers. The mechanism may be that the existence of other inhibitory pathways. T-cell immunoglobulin mucin molecule -3T cell immunolobulin and mucin-containing protein-3pTIM-3 is an immunological checkpoint molecule that can be expressed in a variety of immune cells and plays an important regulatory role. It has been reported that there is a high expression of TIM-3 in peripheral blood and infiltrating T cells of many kinds of tumors, and it is associated with poor prognosis. In anti-tumor immunity, T cell DC and mononuclear macrophages, which express high TIM-3, can inhibit tumor immune response. Pre-clinical studies showed that monoclonal antibodies against TIM-3 and PD-1 could play a synergistic effect on tumor. TIM-3 monoclonal antibody had entered the clinical trial stage. However, some functions of TIM-3 in regulating immune cells need to be clarified. Further understanding the immunomodulatory mechanism of TIM-3 is helpful to promote the clinical application based on blocking TIM-3 anti-tumor immunotherapy.
【作者单位】：上海交通大学医学院附属新华医院血液内科;
【基金】：上海市教育委员会高峰高原学科建设资助项目(No.20152219)~~
【分类号】：R730.51

【相似文献】